Artrya Limited (AYAUF) Q1 2027 Earnings Call Transcript
Artrya Limited (AYAUF) Q1 2027 Earnings Call October 25, 2026 8:01 PM EDT
Company Participants
John Konstantopoulos – Co-Founder & CEO
Clayton Hatch – Chief Financial Officer
Conference Call Participants
David Allen – Hawkesbury Partners Pty Limited
Presentation
David Allen
Hawkesbury Partners Pty Limited
Hello, and welcome everyone to the Artrya Investor Call for the September 2026 quarterly results and outlook. My name is David Allen from Hawkesbury Partners. I’m going to be your host for today’s call. And joining us is John Konstantopoulos, CEO and Co-Founder, in Atlanta, Georgia. And with him, we also have Clayton Hatch, CFO of Artrya. I’d like to add this call that’s being recorded today. [Operator Instructions] We will also have a recording of today’s call on Artrya’s website for future viewing.
Now I’d like to hand over to John Konstantopoulos, CEO of Artrya to start off today’s call.
John Konstantopoulos
Co-Founder & CEO
Thanks, David, and thanks, everybody, for joining. And as David mentioned, I’m in Atlanta here in Georgia probably for the next 7 to 8 weeks, really here to move a number of initiatives along that we’ve been focusing on. But more importantly, we just want to focus on this past quarter that we’ve just finished off.
For us, commercial execution in the U.S., as we’ve always mentioned, has been a major priority, and we’ve made quite a lot of progress during this quarter. We signed our largest customer to date and continued the rollout across many of our foundation customers and pleasingly, we also saw a material increase in Plaque utilization following the Phase 1 of the preauthorization workflow implementation at Tanner and we continue to build a growing pipeline of inbound interest from U.S. health care systems here in the U.S. And I’ll take you through each of these different initiatives as we go forward before I
